![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland (M.T., R.N., T.J., P.T., O.P.); and Department of Pharmacology and Toxicology, University of Kuopio, Kuopio, Finland (R.N., H.R.)
Some inhibitory agents against CYP2B6 have been reported, but none of these has been extensively characterized or compared with others, as to the potency and selectivity of inhibition toward CYP2B6. The goal of this work was to find a selective and potent chemical in vitro inhibitor toward CYP2B6 using bupropion hydroxylation as a model reaction. At the initial screening of more than 30 substances, ticlopidine, triethylenethiophosphoramide (thioTEPA), metyrapone, xanthate C8, and benzylisothiocyanate displayed IC50 values of <10 µM and were selected for a more detailed analysis. Metyrapone, xanthate C8, and benzylisothiocyanate inhibited several other cytochrome P450 activities rather effectively, some of them even more potently than CYP2B6, and consequently are unsuitable as CYP2B6-selective probes. Ticlopidine and thioTEPA were the most potent inhibitors of bupropion hydroxylation with Ki values of 0.2 and 2.8 µM, respectively. The inhibition type of ticlopidine was found to be mixed type, with a component of mechanism-based inhibition, whereas thioTEPA inhibited CYP2B6 in a competitive manner. In addition to CYP2B6, ticlopidine also inhibited both mephenytoin 4-hydroxylation (CYP2C19) (IC50, 2.7 µM) and dextromethorphan O-demethylation (CYP2D6) (IC50, 4.4 µM). For thioTEPA the next sensitive P450 activity after CYP2B6 was coumarin 7-hydroxylation (IC50, 256 µM). Thus, although both compounds proved to be relatively potent inhibitors of CYP2B6, thioTEPA was about 2 orders of magnitude more selective than ticlopidine. Thus, thioTEPA is a drug of choice when high CYP2B6 selectivity among major P450 enzymes is required. Ticlopidine is a useful alternative under a controlled experimental setup and when higher potency is needed.
This article has been cited by other articles:
|
|
 |
|
  A. J. Lau and T. K. H. Chang Inhibition of Human CYP2B6-Catalyzed Bupropion Hydroxylation by Ginkgo biloba Extract: Effect of Terpene Trilactones and Flavonols Drug Metab. Dispos., September 1, 2009; 37(9): 1931 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nishiya, K. Hagihara, T. Ito, M. Tajima, S.-i. Miura, A. Kurihara, N. A. Farid, and T. Ikeda Mechanism-Based Inhibition of Human Cytochrome P450 2B6 by Ticlopidine, Clopidogrel, and the Thiolactone Metabolite of Prasugrel Drug Metab. Dispos., March 1, 2009; 37(3): 589 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kim, K.-B. Kim, H.-Y. Ku, S.-J. Park, H. Choi, J.-K. Moon, B.-S. Park, J.-H. Kim, S. S. Yea, C.-H. Lee, et al. Identification and Characterization of Potent CYP2B6 Inhibitors in Woohwangcheongsimwon Suspension, an Herbal Preparation Used in the Treatment and Prevention of Apoplexy in Korea and China Drug Metab. Dispos., June 1, 2008; 36(6): 1010 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Kharasch, D. Mitchell, and R. Coles Stereoselective Bupropion Hydroxylation as an In Vivo Phenotypic Probe for Cytochrome P4502B6 (CYP2B6) Activity J. Clin. Pharmacol., April 1, 2008; 48(4): 464 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Stadel, J. Yang, J. W. Nalwalk, J. G. Phillips, and L. B. Hough High-Affinity Binding of [3H]Cimetidine to a Heme-Containing Protein in Rat Brain Drug Metab. Dispos., March 1, 2008; 36(3): 614 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Walsky and R. S. Obach A Comparison of 2-Phenyl-2-(1-piperidinyl)propane (PPP), 1,1',1''-Phosphinothioylidynetrisaziridine (ThioTEPA), Clopidogrel, and Ticlopidine as Selective Inactivators of Human Cytochrome P450 2B6 Drug Metab. Dispos., November 1, 2007; 35(11): 2053 - 2059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Abass, P. Reponen, M. Turpeinen, J. Jalonen, and O. Pelkonen Characterization of Diuron N-Demethylation by Mammalian Hepatic Microsomes and cDNA-Expressed Human Cytochrome P450 Enzymes Drug Metab. Dispos., September 1, 2007; 35(9): 1634 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Volotinen, M. Turpeinen, A. Tolonen, J. Uusitalo, J. Maenpaa, and O. Pelkonen Timolol Metabolism in Human Liver Microsomes Is Mediated Principally by CYP2D6 Drug Metab. Dispos., July 1, 2007; 35(7): 1135 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Walsky, A. V. Astuccio, and R. S. Obach Evaluation of 227 Drugs for In Vitro Inhibition of Cytochrome P450 2B6. J. Clin. Pharmacol., December 1, 2006; 46(12): 1426 - 1438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. N. Bumpus, U. M. Kent, and P. F. Hollenberg Metabolism of Efavirenz and 8-Hydroxyefavirenz by P450 2B6 Leads to Inactivation by Two Distinct Mechanisms J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 345 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. McCune, L. J. Risler, B. R. Phillips, K. E. Thummel, D. Blough, and D. D. Shen CONTRIBUTION OF CYP3A5 TO HEPATIC AND RENAL IFOSFAMIDE N-DECHLOROETHYLATION Drug Metab. Dispos., July 1, 2005; 33(7): 1074 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N. Bumpus, C. Sridar, U. M. Kent, and P. F. Hollenberg THE NATURALLY OCCURRING CYTOCHROME P450 (P450) 2B6 K262R MUTANT OF P450 2B6 EXHIBITS ALTERATIONS IN SUBSTRATE METABOLISM AND INACTIVATION Drug Metab. Dispos., June 1, 2005; 33(6): 795 - 802. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
